This study demonstrates that pitolisant, an FDA‐approved H3R antagonist, effectively suppresses EtOH‐induced locomotor stimulation and reward, reduces voluntary alcohol consumption, and alleviates withdrawal‐induced anxiety and depression‐like behaviors in mice. Here, HRH3 is linked to depressive disorder.